KCG Holdings Inc. Sells 86,355 Shares of Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX)
KCG Holdings Inc. lowered its stake in shares of Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) by 75.0% during the first quarter, according to its most recent filing with the SEC. The fund owned 28,739 shares of the specialty pharmaceutical company’s stock after selling 86,355 shares during the period. KCG Holdings Inc.’s holdings in Pernix Therapeutics Holdings were worth $106,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in the stock. Bank of New York Mellon Corp boosted its stake in shares of Pernix Therapeutics Holdings by 27.8% in the first quarter. Bank of New York Mellon Corp now owns 31,710 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 6,907 shares during the period. California Public Employees Retirement System bought a new stake in shares of Pernix Therapeutics Holdings during the first quarter valued at about $163,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Pernix Therapeutics Holdings by 6.9% in the first quarter. Renaissance Technologies LLC now owns 740,650 shares of the specialty pharmaceutical company’s stock valued at $2,740,000 after buying an additional 47,700 shares during the period. 15.63% of the stock is currently owned by institutional investors and hedge funds.
Shares of Pernix Therapeutics Holdings, Inc. (PTX) traded down 7.4590% during mid-day trading on Friday, hitting $2.4801. The stock had a trading volume of 106,582 shares. Pernix Therapeutics Holdings, Inc. has a 12 month low of $0.40 and a 12 month high of $7.15. The firm’s market cap is $27.57 million. The stock’s 50-day moving average is $3.75 and its 200 day moving average is $3.81.
Pernix Therapeutics Holdings (NASDAQ:PTX) last announced its earnings results on Thursday, July 27th. The specialty pharmaceutical company reported ($2.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($4.40) by $2.24. The firm had revenue of $34.32 million for the quarter. Equities research analysts predict that Pernix Therapeutics Holdings, Inc. will post ($3.70) earnings per share for the current fiscal year.
Separately, ValuEngine lowered Pernix Therapeutics Holdings from a “sell” rating to a “strong sell” rating in a report on Saturday, July 8th.
Pernix Therapeutics Holdings Company Profile
Pernix Therapeutics Holdings, Inc is a specialty pharmaceutical company. The Company focuses on identifying, developing and commercializing differentiated products that address unmet medical needs. It focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas.
Want to see what other hedge funds are holding PTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX).
Receive News & Ratings for Pernix Therapeutics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pernix Therapeutics Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.